title: [Clinical studies of newly diagnosed prostate cancer].
abstract: BACKGROUND
  The objective of this study is to report the outcome of various treatments in patients who were newly diagnosed prostate cancer from May 1984 to December 1994, at a single institution.
  
  
  METHODS
  A retrospective study was carried out in the 142 patients.
  
  
  RESULTS
  Total retropubic prostatectomy were performed in 52 patients (37%). The 5-year survival rates (Kaplan-Meier) in the patients with total prostatectomy were 89% in stage B (24), 86% in stage C (7), and 87% in stage D1 (17), respectively. Endocrine therapies (33) or endocrine therapies in combination with chemotherapies (37) as a initial therapy for stage D2 were performed. Among these therapies, endocrine therapy in combination with cyclophosphamide (700 mg/m2/4 weeks, i.v.) was superior to any of the other treatments in stage D2. The response rate, median response duration and median survival time in this combination therapy were 83%, 29 months and 49 months. The overall 3, 5, and 10-year survival rate in the 142 patients were 67%, 51% and 26%, respectively. The 5-year survival rates according to grade were 73% in grade 1, 45% in grade 2, 42% in grade 3, respectively.
  
  
  CONCLUSIONS
  The 5-year survival rates in pathological stage C and D1 patients who received adjuvant hormone and radiation therapy after radical prostatectomy were 86% and 87%. The most effective therapy for stage D2 was hormone in combination with cyclophosphamide. The response rate and median response duration were 83% and 29 months.
authors.affiliation: Department of Urology, Hyogo Medical Center for Adults.
authors.forename: A
authors.initials: A
authors.lastname: Fujii
authors.forename: K
authors.initials: K
authors.lastname: Gohji
authors.forename: K
authors.initials: K
authors.lastname: Morisue
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: M
authors.initials: M
authors.lastname: Nomi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002715:Chlormadinone Acetate / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D045167:Progesterone Congeners / Q000627:therapeutic use; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D045167:Progesterone Congeners; D002715:Chlormadinone Acetate; D004054:Diethylstilbestrol; D003520:Cyclophosphamide; C004955:fosfestrol